Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma

Phase 1 Completed 43 enrolled University Hospital, Grenoble NETRIS Pharma · collab

NaSingle-groupOpen-labelTreatment

Summary

The study will assess the safety of the association of NP137 with the standard of care mFOLFIRINOX in the treatment of locally advanced pancreatic ductal adenocarcinoma.The study drug which is tested is the NP137 in association with mFOLFIRINOX to allow a better tumor response as well as better survival outcomes with an acceptable safety.

Timeline

Start: 2023-03-28
Primary completion: 2024-12-09
Completion: 2025-06-16

Publications

Roth G, Artru P, Bouche O, Williet N, Ghelfi J, Turpin A, Lievre A, Blanc JF, Evrard C, Bachet JB, Parent P, Manceau M, Roustit M, Borowik A, Granger V, Durand A, d'Engremont C, Girard E, Chirica M, Braissand N, Rama N, Modolo E, Hernandez-Vargas H, Georges E, Scoazec JY, Cros J, Hazard S, Ducarouge B, Decaens T, Bernet A, Mehlen P. Netrin1 blockade alleviates resistance to chemotherapy in pancreatic cancer. Nature. 2026 Jun;654(8119):798-805. doi: 10.1038/s41586-026-10436-4. Epub 2026 Apr 22.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	NP137	Monoclonal antibody	9 mg/kg	Intravenous
Subject	NP137	Monoclonal antibody	14 mg/kg	Intravenous
Background	Irinotecan	Small molecule	150 mg/m2	Intravenous
Background	Levoleucovorin	Unknown	100 mg/m2	Intravenous
Background	Oxaliplatin	Small molecule	85 mg/m2	Intravenous
Background	fluorouracil	Small molecule	2400 mg/m2	Intravenous

Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma

Summary

Timeline

Publications

Drugs

Indications